A new Fabry disease therapy, PRX-102 (pegunigalsidase alfa), has been given marketing authorization by the European Medicines Agency.
Developed by Israel’s Protalix BioTherapeutics (TASE: PLX) and Italian partner Chiesi Farmaceutici, approval for the enzyme replacement therapy was expected after the EMA’s scientific advisors issued a positive decision earlier in the year.
The product will vie with two other therapies in this class which are already available in Europe - Sanofi’s (Euronext: SAN) Fabrazyme (agalsidase beta) and Takeda’s (TYO: 4502) Replagal (agalsidase alfa).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze